Yuhan Corporation (KRX:000100)
South Korea
· Delayed Price · Currency is KRW 118,800
-1,100 (-0.92%)
Mar 12, 2025, 9:00 AM KST
Yuhan Revenue
Yuhan had revenue of 598.78B KRW in the quarter ending September 30, 2024, with 23.96% growth. This brings the company's revenue in the last twelve months to 2.01T, up 7.29% year-over-year. In the year 2023, Yuhan had annual revenue of 1.86T with 4.68% growth.
Revenue (ttm)
2,008.84B
Revenue Growth
+7.29%
P/S Ratio
4.69
Revenue / Employee
1.00B
Employees
1,999
Market Cap
8,975.70B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 1,858.98B | 83.14B | 4.68% |
| Dec 31, 2022 | 1,775.85B | 88.04B | 5.22% |
| Dec 31, 2021 | 1,687.81B | 67.95B | 4.19% |
| Dec 31, 2020 | 1,619.87B | 139.51B | 9.42% |
| Dec 31, 2019 | 1,480.35B | -38.47B | -2.53% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,547.32B |
| Celltrion | 2,876.25B |
| ALTEOGEN | 74.38B |
| HLB Co., Ltd. | 51.92B |
| SK Biopharmaceuticals | 511.33B |
| Sam Chun Dang Pharm. | 208.22B |
| LigaChem Biosciences | 101.42B |
| PharmaResearch | 317.00B |